The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Activity of VEGF-C is tested by the stimulation of VEGF-R3 phosphorylation in cells transfected with VEGF-R3. The expected ED50 is > 200 ng/ml.
% SDS-PAGE. Endotoxin level is <0.1 ng per g of VEGF-C
Recombinant VEGF-C (Vascular Endothelial Growth Factor-C) is a 125 amino acid protein that lacks the N-terminal signal peptide
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped at 4°C. Upon delivery aliquot. Store at -80°C. Avoid freeze / thaw cycle.
This product is an active protein and may elicit a biological response in vivo, handle with caution.
Reconstitutionreconstitution in 0.1% acetic acid to a concentration of 0.1-1.0 mg/ml.
FLT4 ligand DHM
Vascular endothelial growth factor C
Vascular endothelial growth factor related protein
Vascular endothelial growth factor-related protein
FunctionGrowth factor active in angiogenesis, and endothelial cell growth, stimulating their proliferation and migration and also has effects on the permeability of blood vessels. May function in angiogenesis of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Binds and activates VEGFR-2 (KDR/FLK1) and VEGFR-3 (FLT4) receptors.
Tissue specificitySpleen, lymph node, thymus, appendix, bone marrow, heart, placenta, ovary, skeletal muscle, prostate, testis, colon and small intestine and fetal liver, lung and kidney, but not in peripheral blood lymphocyte.
Sequence similaritiesBelongs to the PDGF/VEGF growth factor family.
Post-translational modificationsUndergoes a complex proteolytic maturation which generates a variety of processed secreted forms with increased activity toward VEGFR-3, but only the fully processed form could activate VEGFR-2. VEGF-C first form an antiparallel homodimer linked by disulfide bonds. Before secretion, a cleavage occurs between Arg-227 and Ser-228 producing an heterotetramer. The next extracellular step of the processing removes the N-terminal propeptide. Finally the mature VEGF-C is composed mostly of two VEGF homology domains (VHDs) bound by non-covalent interactions.